Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting

Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively treated by ≥ 3 prior lines of therapy. BCMA/CD3 and GPR...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Jiangxue, Li, Yufu, Lin, Quande
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463662/
https://www.ncbi.nlm.nih.gov/pubmed/37633955
http://dx.doi.org/10.1186/s40164-023-00436-9
_version_ 1785098284457525248
author Hou, Jiangxue
Li, Yufu
Lin, Quande
author_facet Hou, Jiangxue
Li, Yufu
Lin, Quande
author_sort Hou, Jiangxue
collection PubMed
description Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively treated by ≥ 3 prior lines of therapy. BCMA/CD3 and GPRC5D/CD3 are the most popular combinations. Clinical findings indicated that patients exhibit a greater susceptibility to stronger and more enduring responses. Here, we summarize the latest data from the 2023 ASCO annual meeting on BsAbs targeting BCMA/CD3, GPRC5D/CD3 and BCMA/CD19 CAR T cells. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-023-00436-9.
format Online
Article
Text
id pubmed-10463662
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104636622023-08-30 Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting Hou, Jiangxue Li, Yufu Lin, Quande Exp Hematol Oncol Correspondence Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively treated by ≥ 3 prior lines of therapy. BCMA/CD3 and GPRC5D/CD3 are the most popular combinations. Clinical findings indicated that patients exhibit a greater susceptibility to stronger and more enduring responses. Here, we summarize the latest data from the 2023 ASCO annual meeting on BsAbs targeting BCMA/CD3, GPRC5D/CD3 and BCMA/CD19 CAR T cells. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-023-00436-9. BioMed Central 2023-08-26 /pmc/articles/PMC10463662/ /pubmed/37633955 http://dx.doi.org/10.1186/s40164-023-00436-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Hou, Jiangxue
Li, Yufu
Lin, Quande
Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
title Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
title_full Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
title_fullStr Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
title_full_unstemmed Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
title_short Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
title_sort bispecific antibodies and dual-targeting car-t cells for multiple myeloma: latest updates from the 2023 asco annual meeting
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463662/
https://www.ncbi.nlm.nih.gov/pubmed/37633955
http://dx.doi.org/10.1186/s40164-023-00436-9
work_keys_str_mv AT houjiangxue bispecificantibodiesanddualtargetingcartcellsformultiplemyelomalatestupdatesfromthe2023ascoannualmeeting
AT liyufu bispecificantibodiesanddualtargetingcartcellsformultiplemyelomalatestupdatesfromthe2023ascoannualmeeting
AT linquande bispecificantibodiesanddualtargetingcartcellsformultiplemyelomalatestupdatesfromthe2023ascoannualmeeting

Ejemplares similares